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Abstract 31 
 32 
Objective: Chemoresistance is a critical feature of advanced ovarian cancer with only 30% of 33 
patients surviving longer than 5 years. We have previously shown that four kallikrein–related 34 
(KLK) peptidases, KLK4, KLK5, KLK6 and KLK7 (KLK4–7), are implicated in peritoneal 35 
invasion and tumour growth, but underlying mechanisms were not identified. We also reported 36 
that KLK7 overexpression confers chemoresistance to paclitaxel, and cell survival via integrins. 37 
In this study, we further explored the functional consequenses of overexpression of all four 38 
KLKs (KLK4–7) simultaneously in the ovarian cancer cell line, OV–MZ–6, and its impact on 39 
integrin expression and signalling, cell adhesion and survival as contributors to chemoresistance 40 
and metastatic progression. 41 
Methods: Quantitative gene and protein expression analyses, confocal microscopy, cell adhesion 42 
and chemosensitivity assays were performed. 43 
Results: Expression of α5β1/αvβ3 integrins was downregulated upon combined stable KLK4–7 44 
overexpression in OV–MZ–6 cells. Accordingly, the adhesion of these cells to vitronectin and 45 
fibronectin, the extracellular matrix binding proteins of α5β1/αvβ3 integrins and two 46 
predominant proteins of the peritoneal matrix, was decreased. KLK4–7–transfected cells were 47 
more resistant to paclitaxel (10–100 nmol/L: 38–54%), but not to carboplatin, which was 48 
associated with decreased apoptotic stimuli. However, the KLK4–7–induced paclitaxel 49 
resistance was not blocked by the MEK1/2 inhibitor, U0126. 50 
Conclusions: This study demonstrates that combined KLK4–7 expression by ovarian cancer 51 
cells promotes reduced integrin expression with consequently less cell–matrix attachment, and 52 
insensitivity to paclitaxel mediated by complex integrin and MAPK independent interactions, 53 
indicative of a malignant phenotype and disease progression suggesting a role for these KLKs in 54 
this process. 55 
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3 
Introduction 61 
 62 
Ovarian cancer is the most common malignancy among gynaecological cancers and is the major 63 
cause of all female cancer deaths [1, 2]. The predominant cancer type is epithelial ovarian 64 
carcinoma (EOC). More than 75% of ovarian cancer patients are diagnosed at a late–stage with 65 
evidence of metastatic spread within the peritoneal cavity and pelvic region. Cytoreductive 66 
surgery and chemotherapy is the standard treatment for advanced ovarian cancer. Although 67 
platinum–taxane combination therapies have improved, the 5 year survival rate of patients is 68 
only 30% with the overall mortality due to relapse and chemoresistance unchanged for decades. 69 
The main reasons for unsuccessful therapies are a limited understanding of the heterogeneous 70 
pathobiology of this disease, the mechanisms underlying drug resistance and a limited number of 71 
prognostic and therapeutic biomarkers [2-4]. 72 
 73 
Currently, the serum biomarker CA125 is clinically used to indicate the presence of ovarian 74 
cancer, although not all patients have elevated CA125 levels and its detection can result in false 75 
positives. Due to the low specificity and sensitivity, its use for monitoring treatment responses 76 
and predicting prognosis after treatment is limited. Therefore, novel ovarian cancer–specific 77 
serum biomarkers are needed to detect this disease and to follow up patient outcomes [5]. 78 
Cancer–related proteases, such as kallikrein–related peptidases (KLK; proteins encoded by KLK 79 
genes), are under investigation as potential diagnostic indicators for ovarian cancer and 80 
prognostic biomarkers for disease progression [6-9]. Among the fifteen human KLKs, twelve, 81 
including KLK4, KLK5, KLK6, and KLK7 (KLK4–7), are up–regulated in cancerous ovarian 82 
tissues, serum and ascites fluid from patients, and cell lines [6, 10, 11]. KLK5 serves as a 83 
biomarker for early detection of ovarian cancer and its levels in serum or ascites fluid did not 84 
correlate with the established cancer biomarker CA125, thus it provides independent information 85 
from CA125 in this disease [12]. KLK4–7 overexpression is associated with late–stage and high–86 
grade disease, shorter disease–free and overall survival rates [12]. Elevated serum levels of 87 
KLK4–7 are associated with non–responsiveness of ovarian cancer patients to paclitaxel [9, 12-88 
14]. Both KLK/KLK4 and KLK/KLK7 are also associated with multicellular aggregation and 89 
paclitaxel resistance in ovarian cancer in vitro [13, 14]. KLKs likely play a crucial role 90 
throughout the progression of ovarian cancer by contributing to invasion, metastasis and 91 
4 
modification of the tumour microenvironment via degradation and/or activation of extracellular 92 
matrix (ECM) and other proteins leading to altered cell–cell/cell–ECM interactions, ECM 93 
remodelling, cell survival and differentiation [15]. However, the precise signalling pathways 94 
involved are not yet fully elucidated. 95 
 96 
Cell–cell/cell–ECM adhesion molecules, such as integrin cell adhesion and signalling receptors 97 
are also critical factors in tumour progression. Integrin signalling is involved in multiple 98 
functions of tumour cells, such as adhesion, invasion, proliferation, survival and apoptosis, 99 
thereby affecting tumour growth and metastasis [16]. Integrins are non–covalently associated 100 
heterodimeric cell surface receptors promoting bidirectional signal transduction via preferential 101 
binding to distinct ECM proteins, such as fibronectin, vitronectin and collagens. Although 102 
transmembrane integrins lack kinase activity, by clustering they recruit and activate kinases, such 103 
as focal adhesion kinase (FAK) and src family kinases (SFK), to form focal adhesions and 104 
crosstalk with other cell surface receptors, thereby activating the MAPK signalling cascade [17]. 105 
Of particular interest, it has been reported for various cancer types including ovarian cancer, that 106 
integrins mediate tumour–ECM interactions, like matrix adhesion and alteration of apoptotic 107 
mediators, leading to drug resistance [18]. Different integrins contribute to tumour progression 108 
and chemoresistance of ovarian cancer. For example, αvβ3, α5β1 and α2β1 integrins are 109 
upregulated in late–stage ovarian cancer [19-21]. 110 
 111 
The objective of this study was to determine the functional consequences on cell adhesion, cell 112 
survival, integrin expression and related signalling responses towards the commonly used 113 
chemo–agents paclitaxel and carboplatin upon stable KLK4–7 overexpression in the EOC cell 114 
line OV–MZ–6 [22, 23]. In this previously generated cell line, combined KLK4–7 transfection 115 
promoted increased invasion in vitro and enhanced tumour growth in an EOC mouse model 116 
compared to vector controls [22], although the underlying mechanisms involved were not 117 
studied. An advantage of this model is that simultaneous expression of KLK4, KLK5, KLK6, 118 
and KLK7 in EOC cells allows their proposed activation cascades which have been described in 119 
vitro by pro–KLK fusion protein digestions on cleavage of the pro–region [24] to proceed. For 120 
instance, KLK4 and KLK5 autoactivate; active KLK4 activates KLK5 and KLK6; active KLK5 121 
activates KLK6 and KLK7; and KLK6 partially activates KLK5 [24]. Although one should be 122 
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circumspect in extrapolation of this data to an in vivo environment, especially considering many 123 
additional potential interactions of (pro)KLKs within the extracellular proteolytic web, several 124 
tissue–specific KLK cascades have been described in detail, for instance, within the central 125 
nervous system, semen or skin [24-27]. In fact, we only saw the marked tumorigenic effect when 126 
the four KLKs (KLK4–7), and not the individual KLKs or other combinations, were 127 
overexpressed in OV–MZ–6 cells [22]. Therefore, it is not unreasonable to assume that an 128 
activation cascade, dependent on combined expression of certain KLKs, akin to that described by 129 
Yoon and colleagues [24], is operational in these cells. 130 
 131 
We demonstrate that stable overexpression of KLK4–7 by EOC cells promoted decreased cell 132 
adhesion to ECM proteins and integrin expression as well as paclitaxel–induced chemoresistance 133 
accompanied by differential expression of drug–resistance associated genes representative of a 134 
malignant phenotype and disease progression. Our results also showed that integrin and MAPK 135 
independent pathways may mediate the cellular responses of KLK4–7–expressing EOC cells that 136 
contribute to their chemoresistance. 137 
 138 
139 
6 
Materials and Methods 140 
 141 
DNA constructs, generation of stable cell lines and cell culture. Human KLK4, KLK5, 142 
KLK6, and KLK7 cDNA including pre–pro–domains were isolated from EOC tissue, stable 143 
KLK–expressing OV–MZ–6 cells generated using G418–selection (1 g/ml; Invitrogen, 144 
Mulgrave, VIC, Australia) and grown in DMEM (Invitrogen) containing 10% (v/v) FCS as 145 
described previously [22]. The human EOC cell line OVCAR–3 was purchased from American 146 
Type Culture Collection (ATCC). Cells were cultured at 37°C/5% COR2R until reaching 147 
confluency of 60–80% and harvested with EDTA (0.48 mmol/L; Invitrogen). 148 
 149 
Cell adhesion assays. Attachment of cells onto the ECM proteins (10 µg/ml) fibronectin (FN) 150 
(BD Biosciences, Eight Mile Plains, QLD, Australia), vitronectin (VN) (Promega, Alexandria, 151 
NSW, Australia), collagen (Col) type I (Sigma–Aldrich, Castle Hill, NSW, Australia) and type 152 
IV (Calbiochem, South Granville, NSW, Australia) and the effect of blocking β1 (#P2D5)/αv 153 
(#AV1) integrin antibodies (Chemicon, North Ryde, NSW, Australia) or mouse IgG (10 µg/ml; 154 
Sigma–Aldrich) was measured as reported previously [13]. For each condition, three different 155 
biological assays were conducted in triplicate and normalised to BSA–coated plates and non–156 
blocked controls. 157 
 158 
Cell survival post paclitaxel/carboplatin/U0126 treatment. Chemosensitivity assays using 159 
anti–cancer agents (Sigma–Aldrich) were performed as reported previously [28]. Briefly, 1 day 160 
after seeding (3.0x10 P4P cells) onto 96–well plates (Perkin Elmer, Melbourne, VIC, Australia), 161 
cells were treated with paclitaxel (0, 0.01, 0.1, 1, 2.5, 5, 10, 50, 100 nmol/L), carboplatin (0, 1, 5, 162 
10, 50, 100 µmol/L) for 3 days, and in 1 day intervals using paclitaxel (100 nmol/L), carboplatin 163 
(50 µmol/L) or in combination; control agents (DMSO (Merck, Kilsyth, VIC, Australia) or 164 
HR2RO). For inhibition, 1 day before seeding, cells were serum–starved with media containing 1% 165 
(v/v) FSC cells, and then pre–treated with the MEK1/2 inhibitor (U0126; 50 µmol/L; Cell 166 
Signaling Technology, Arundel, QLD, Australia) or control agent (DMSO) for 2 h followed by 167 
paclitaxel (100 nmol/L) over 3 days. Cell survival post anti–cancer agents or inhibition was 168 
detected using CyQuant P®P/AlamarBlueP®P assays (Invitrogen) and DNA content/metabolic activity 169 
calculated as percentage of fluorescence in non–treated control samples. The percentage of OV–170 
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Vector cells was set to 100% for each dose and the proportion of OV–KLK4–7 cell survival 171 
calculated from this reference level. For each condition, three different biological assays were 172 
conducted in triplicate. 173 
 174 
Confocal laser scanning microscopy (CLSM). Cell monolayers grown on glass coverslips were 175 
processed as described earlier [28]. Primary [α5 (1:50), β1 (1:200), α5β1 (1:50; #JBS5) integrins 176 
(Chemicon); α–tubulin (1:200; #236–10501; Invitrogen); KLK4 (1:200), KLK7 (1:20), both 177 
generated in Prof Magdolen’s laboratory (Technical University of Munich, Germany); KLK5 178 
(1:100; (#193318; R&D Systems, Gymea, NSW, Australia); KLK6 (1:100; (#265508; R&D 179 
Systems); cytokeratin8 (1:300; #M20; #EP1628Y; Abcam, Waterloo, NSW, Australia); annexin 180 
V (1:200; Abcam)] and secondary [Alexa488/568–conjugated anti–mouse/rabbit IgG (1:1000; 181 
Invitrogen)] antibodies in 1% (w/v) BSA/PBS were incubated for 1 h each. Secondary antibody 182 
only or mouse IgG served as negative controls. F–actin filaments were stained with 183 
rhodamine415–conjugated phalloidin (0.3 U/ml; Invitrogen) and nuclei with DAPI (2.5 mg/ml; 184 
Invitrogen) in 1% (w/v) BSA/PBS. Additionally, cells were labelled with propidium iodide 185 
(1:2000; Invitrogen). Immunofluorescence was visualized and photographed using a confocal 186 
microscope (TCS SP5 II, Leica) with a 20/40x immersion oil objective applying the Leica 187 
Microsystems LAS AF software (version 1.8.2 build 1465). Cells were imaged at five different 188 
positions from three different biological assays. 189 
 190 
Quantitative RT–PCR (RT–qPCR). Equal amounts (1 µg) of total RNA extracted from cells 191 
using TRIzol P®P were treated with DNase 1, reverse transcribed using random hexamers and 192 
cDNA synthesized with SuperScript III. RT–qPCR was performed in triplicate with SYBR 193 
Green chemistry (all PCR reagents from Invitrogen) on an ABI7300 thermal cycler (Applied 194 
Biosystems). Reaction setup and normalization applying the standard curve method (R P2 P 0.99–195 
0.96) were conducted as reported previously [28]. Gene specific primers are listed in 196 
Supplementary Table 1. 197 
 198 
Flow cytometry. Cells (4x10P5P) were blocked with 1% (w/v) BSA/PBS for 30 min and treated 199 
with fluorescein isothiocyanate–conjugated α5 (1:250; #SAM–1)/β1 (1:500; #P4G11) integrins 200 
and phycoerythrin–conjugated αvβ3 integrin (1:500; #LM609) antibodies (Chemicon) for 1.5 h, 201 
8 
washed twice with PBS and resuspended in 0.4 ml PBS for analysis with CXP software (version 202 
2.0) on a flow cytometer FC500 (Beckman Coulter). Mouse IgG (1:500) incubated for 1 h, 203 
followed by Alexa488/568–conjugated anti–mouse IgG (1:1000), incubated for 30 min, served 204 
as control. Flow cytometric analyses were performed under identical instrumental settings 205 
analysing 2x10 P4P events. Signals from subcellular debris were eliminated during data acquisition 206 
by gating. Values of mean fluorescence intensities of triplicates are depicted and normalized to 207 
gated cell numbers and vector controls. 208 
 209 
Western blotting. To determine activation of signalling pathways, cells were serum–starved 210 
over 24 h and treated with paclitaxel (100 nmol/L)/carboplatin (5 µmol/L)/combination of both 211 
agents for 5 min or for inhibition studies with blocking β1 integrin antibody (10 µg/ml), Src 212 
(SU6656; 10 µmol/L; Invitrogen) or MEK1/2 inhibitors (U0126; 50 µmol/L) and control agent 213 
(DMSO) for 2 h. Cells were collected in lysis buffer [50 mmol/L HEPES (pH 7.5); 150 mmol/L 214 
NaCl; 1 mmol/L EDTA; 10% (v/v) glycerol; 1% (v/v) triton X–100; 10 mmol/L sodium 215 
pyrophosphate; 0.1% (w/v) protease inhibitor cocktail (Roche Diagnostic, Castle Hill, NSW, 216 
Australia); 10 mmol/L sodium fluoride; 2 mmol/L sodium vanadate] and protein concentrations 217 
analysed by the 2Tbicinchoninic acid assay (Invitrogen)2T. Cell lysates (20 μg) were electrophoresed 218 
on 10% SDS–PAGE, transferred onto nitrocellulose membranes and treated with OdysseyP®P 219 
blocking buffer (LI–COR Biosciences, Surrey Hills, VIC, Australia). Membranes were incubated 220 
with primary [phospho–p44/42 MAPK (1:1000; #E10; Thr202/Tyr204; Cell Signaling 221 
Technology); p44/42 MAPK (1:1000; Cell Signaling Technology); phospho–Src (1:250; #9A6; 222 
Tyr416; Chemicon); Src (1:250; #GD11; Chemicon); α5 integrin (1:500); β1 integrin (1:500); 223 
GAPDH (1:10 000; Abcam)] and secondary [IRDye 680/800–conjugated rabbit/mouse IgG 224 
(1:5000; LI–COR Biosciences)] antibodies overnight at 4°C and 1 h at room temperature 225 
respectively. Images were taken using the Odyssey system (LI–COR Biosciences). Signal 226 
intensities were recorded by densitometry and averaged from at least three different Western blot 227 
analyses. 228 
 229 
Statistics. Statistical analyses were carried out using an ANOVA and Student’s t–test with the 230 
software ‘R’ (version 2.14.0). Results with ‘P’ value less than 0.05 were considered to indicate 231 
statistically significant differences (* – P<0.05; ** – P<0.01; *** – P<0.001). 232 
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Results 235 
 236 
Combined KLK4–7 expression leads to decreased cell adhesion and integrin expression 237 
Expression of all four KLKs in the transfected OV–MZ–6 cell line (OV–KLK4–7) was 238 
confirmed by RT–qPCR (Figure 1A) and immunofluorescence (Figure 1B) at similar levels to 239 
that reported [22]. Notably, the expression levels of KLK4–7 are in comparable properties to that 240 
seen endogenously in the OVCAR–3 EOC cells (Figure 1A). OV–MZ–6 cells transfected with 241 
empty vector (‘OV–Vector’) and non–transfected parental OV–MZ–6 cells behaved identically 242 
in all assays. In our previous study, we detected increased invasion through Matrigel, but no 243 
difference in cell proliferation for OV–KLK4–7 compared to OV–Vector cells [22]. Herein, we 244 
sought to further explore the mechanisms underlying this invasive ability contributing to 245 
metastatic progression. Analysis of their adhesive capacity to ECM proteins, indicative of the 246 
EOC microenvironment, showed that attachment of OV–KLK4–7 cells to fibronectin (FN) and 247 
vitronectin (VN) was significantly decreased compared to vector controls, but unchanged on 248 
type–I (Col I) and type–IV (Col IV) collagens (Figure 2A). Using a blocking β1 integrin 249 
antibody to the FN receptor, α5β1 integrin, the adhesive behaviour of both OV–KLK4–7/OV–250 
Vector cells to FN was reduced compared to IgG controls (Figure 2B; left panel). Upon αv 251 
integrin blocking of the VN receptor, αvβ3 integrin, attachment of both OV–KLK4–7/OV–252 
Vector cells to VN was reduced, with OV–KLK4–7 cells being less adhesive than vector 253 
controls. Adhesion of OV–KLK4–7 cells on FN increased by αv integrin blocking compared to 254 
vector controls (Figure 2B; right panel). 255 
 256 
Next, we wanted to examine whether the reduced adhesive ability upon combined KLK4–7 257 
expression was linked to an altered integrin expression. Indeed, significantly decreased mRNA 258 
levels of αv/α5/β1 integrins in OV–KLK4–7 compared to OV–Vector cells were detected by 259 
RT–qPCR; β3 integrin did not change (Figure 2C). A similar finding was apparent at the protein 260 
level on performing flow cytometry. Both OV–KLK4–7/OV–Vector cells expressed high levels 261 
of α5/β1 integrins (OV–KLK4–7/OV–Vector: α5 – 2.8±0.7/3.3±0.7 units, β1 – 8.4±0.4/10.6±0.8 262 
units) and minor amounts of αvβ3 integrin (OV–KLK4–7/OV–Vector: 0.004±0.003/0.013±0.004 263 
units; Figure 2D; left panel). Upon normalisation to vector controls, expression of αvβ3/β1 264 
integrins in OV–KLK4–7 cells declined significantly, with α5 integrin showing a clear trend to 265 
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lower levels (Figure 2D; right panel). Using confocal laser scanning microscopy (CLSM), less 266 
transmembrane fluorescent staining of α5/β1/α5β1 integrins was visualised in OV–KLK4–7 267 
compared to OV–Vector cells (Figure 2E); αvβ3 integrin staining was not detectable (data not 268 
shown). These results suggest that the invasive ability of KLK4–7–expressing EOC cells is due, 269 
at least in part, to a decreased adhesive capacity to VN/FN, known components of the peritoneal 270 
ECM, and mediated by decreased α5/β1/αvβ3 integrin expression. 271 
 272 
Paclitaxel–induced chemoresistance of OV–KLK4–7 cells 273 
Ovarian cancer cells have an enhanced resistance to anti–cancer agents, including paclitaxel and 274 
cisplatin/carboplatin [13, 29, 30]. Previously, it was shown that KLK4 and KLK7, in particular, 275 
play a role in chemoresistance of EOC cells [13, 14]. Hence, we determined the effect of the 276 
chemo–agents, paclitaxel and carboplatin, on OV–KLK4–7 cells. Exposure to paclitaxel (0.01–277 
100 nmol/L) over 3 days caused a strong reduction of cell survival. However, compared to vector 278 
controls, a significant increased cell survival at a dose of 10–100 nmol/L in OV–KLK4–7 cells 279 
was observed (10 nmol/L – 38%, 50 nmol/L – 49%, 100 nmol/L – 54% equivalent to the 280 
proportion of OV–Vector cell survival; Figure 3A). In contrast, the combined expression of 281 
KLK4–7 in OV–MZ–6 cells did not change the chemosensitivity of these cells to carboplatin (1–282 
100 µmol/L) treatment at a dose of 10–100 µmol/L (Figure 3B). 283 
Since platinum–taxane–based combination chemotherapy is more routinely given to patients, we 284 
determined the effects of this combined treatment on OV–KLK4–7 cells. Hereby, 285 
chemoresistance of OV–KLK4–7 cells to paclitaxel (100 nmol/L) was confirmed either when 286 
given on day 1 followed by 2 days with media only (P–M–M; 118% equivalent to the proportion 287 
of OV–Vector cell survival) or on day 3 after 2 days with media only (M–M–P; 24% equivalent 288 
to the proportion of OV–Vector cell survival). Paclitaxel–induced cell death was not further 289 
increased upon combined treatment with carboplatin either when cells were treated on day 1 with 290 
paclitaxel followed by media only on day 2 and carboplatin (50 µmol/L) on day 3 (P–M–C; 291 
114% compared to vector controls) or in combination with paxlitaxel on day 3 (C–M–P; 20% 292 
equivalent to the proportion of OV–Vector cell survival; Figure 3C). Accordingly, carboplatin 293 
had no effect whether added on day 1 or day 3 alone (C–M–M/M–M–C; Figure 3C). 294 
 295 
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To determine that the induced changes to paclitaxel sensitivity were indicative of that observed 296 
in both cell types, paclitaxel–induced cellular effects were further examined. Paclitaxel enhances 297 
the assembly of stable microtubules from tubulin dimers and inhibits their depolymerisation 298 
resulting in abnormal microtubules [31], microtubule bundles and micronuclei as shown in both 299 
OV–KLK4–7/OV–Vector paclitaxel–treated cells by CLSM (Figure 4A). Consistent with other 300 
reports [32, 33], the OV–MZ–6 cells used here, whether expressing KLK4–7 or not, exhibited 301 
nuclei with variable morphologies on treatment with paclitaxel. About half of the population 302 
exhibited typical oval–shaped nuclei (indicated by yellow arrows), whereas the other half 303 
showed lobulated and multiple micronuclei (indicated by green arrows; Figure 4A). 304 
On paclitaxel (100 nmol/L) treatment over 0–48 h (Figure 4B), caspase8 (indicative of apoptosis 305 
[34]) mRNA levels were significantly decreased in the chemoresistant OV–KLK4–7 cells and 306 
increased in the chemosensitive OV–Vector cells. The cytoskeletal marker cytokeratin8 revealed 307 
a similar trend as caspase8 showing a significant downregulation in chemoresistant OV–KLK4–308 
7 cells and upregulation in chemosensitive OV–Vector cells after treatment. In contrast, 309 
cytokeratin18 was strongly induced in both OV–KLK4–7 (7–fold)/OV–Vector (3–fold) cells 310 
after treatment, with higher levels in OV–KLK4–7 cells (Figure 4B). Paclitaxel–induced cell 311 
death was also depicted by propidium iodide and annexin V fluorescent staining, with less 312 
prominent appearance in chemoresistant OV–KLK4–7 cells (Figure 4C). These results indicate 313 
that combined KLK4–7 expression alters paclitaxel sensitivity, as reflected in these key cellular 314 
markers, in the EOC cell line OV–MZ–6. 315 
 316 
Chemoresponse of OV–KLK4–7 cells is only partially mediated by β1 integrin or MAPK 317 
signalling 318 
Given that α5β1 and αvβ3 integrins play a role in the decreased ECM adhesion of OV–KLK4–7 319 
cells and that integrin–mediated pathways have also been implicated in chemosensitivity [16, 320 
18], we next assessed integrin mRNA expression levels upon paclitaxel treatment (100 nmol/L) 321 
over 0–48 h. Whereas the levels of α5/αv/β1/β3 integrin (representative of cell survival [16]) and 322 
the ECM proteins FN/VN (data not shown) did not change in both OV–KLK4–7/OV–Vector 323 
cells after treatment, the mRNA level of the β1 integrin–related factor CXCR4 was significantly 324 
decreased in chemoresistant OV–KLK4–7 cells compared to OV–Vector cells after treatment 325 
(Table 1). In contrast, in Western blot and densitometry analyses, β1 integrin protein expression 326 
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was significantly upregulated in OV–KLK4–7 cells compared to vector controls upon paclitaxel 327 
treatment (Figure 5A, B); α5 integrin expression did not change (data not shown). The altered β1 328 
integrin level was confirmed by flow cytometry, with αvβ3 integrin being marginally increased 329 
in OV–KLK4–7 cells compared to vector controls upon paclitaxel treatment; α5 integrin levels 330 
did not change (data not shown). These results suggest that the increased chemoresistance of 331 
KLK4–7–expressing EOC cells to paclitaxel maybe only partially due to integrin–mediated cell 332 
survival. 333 
 334 
Next, we wanted to elucidate other signalling mechanisms leading to the enhanced survival of 335 
OV–KLK4–7 cells involved in paclitaxel–induced chemoresistance. Western blot and 336 
densitometry analyses were performed to detect the activation of potentially involved signalling 337 
pathways, such as MAPK, Src, and FAK. Basal expression levels of MAPK, Src (Figure 5A) and 338 
FAK (data not shown) were comparable in both OV–KLK4–7/OV–Vector cells without 339 
treatment. Upon administration of paclitaxel, MAPK, in particular ERK1, showed significantly 340 
increased phosphorylation in OV–KLK4–7 cells compared to vector controls (Figure 5A, B). Src 341 
(Figure 5A, B) and FAK (data not shown) were not activated with these treatments. 342 
 343 
To further support these and our earlier findings, MAPK, Src and integrin–related pathways were 344 
blocked by pre–exposure for 2 hr of cells before paclitaxel treatment to a blocking β1 integrin 345 
antibody and specific Src (SU6656) and MEK1/2 (U0126) inhibitors. While β1 integrin and Src 346 
inhibition had no effect in either cell line, with or without paclitaxel treatment, MEK1/2 347 
inhibition blocked ERK1/2 phosphorylation of both OV–KLK4–7/OV–Vector cells independent 348 
of paclitaxel treatment (Figure 5C). As MAPK signalling was altered upon paclitaxel treatment 349 
in line with other reports [35], we further examined the effect of MEK1/2 inhibition on cell 350 
survival after paclitaxel administration. Survival of OV–KLK4–7 cells was significantly 351 
enhanced upon MEK1/2 inhibition with U0126 before (10 nmol/L – 23%, 100 nmol/L – 54% 352 
equivalent to the proportion of OV–Vector cell survival) and after (10 nmol/L – 56%, 100 353 
nmol/L – 86% equivalent to the proportion of OV–Vector cell survival) paclitaxel treatment 354 
compared to vector controls (Figure 5D). MEK1/2 inhibition alone reduced the growth rates of 355 
both OV–KLK4–7/OV–Vector cells over a time course of 3 days, with OV–KLK4–7 cells 356 
showing a slight increased proliferation (data not shown). These results indicate that the MAPK 357 
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pathway, independent of β1 integrin and Src, is not the major player in the cellular responses of 358 
KLK4–7–expressing EOC cells that contributes to their chemoresistance. 359 
 360 
361 
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Discussion 362 
 363 
The focus of this study was to further dissect the crucial function of kallikreins in ovarian cancer 364 
progression and chemoresistance upon crosstalk with integrins and other cell survival factors. 365 
The data presented here further elaborates our previous studies [13, 22] showing critical effects 366 
for KLK4–7 in peritoneal dissemination and paclitaxel chemoresistance (KLK7 alone). 367 
Herewith, our observation of reduced adhesion to the EOC peritoneal matrix proteins, FN and 368 
VN, mediated by decreased levels of α5/β1/αvβ3 integrins, further supports a role for KLK4–7 in 369 
peritoneal migration and invasion. We also show that paclitaxel–induced chemoresistance was 370 
accompanied by differential expression of drug–resistance associated genes and by an activation 371 
of MAPK signalling that was enhanced in KLK4–7–expressing cells. However, additional 372 
networks initiated by cell surface receptors independent of the MAPK cascade are in play given 373 
the lack of the effect of the MEK1/2 (U0126) inhibitor. 374 
 375 
Role of KLKs, the ECM and integrins in ovarian cancer progression 376 
The underlying mechanisms by which the kallikrein peptidases are involved in the pathogenesis 377 
and progression of ovarian cancer are still not fully understood. Proteolytic factors are crucial 378 
during intra–peritoneal metastasis of ovarian cancer and required at multiple stages, especially 379 
for initial detachment of cancer cells from the surface of the ovary and peritoneal invasion. The 380 
involvement of KLKs in these processes to date has been most specifically related to the 381 
suggested degradation of ECM substrates based on biochemical analyses [36]. For instance, 382 
KLK4 has been shown to degrade fibrinogen [37] and FN, VN (unpublished data), KLK5 and 383 
KLK6 degrade FN, VN, Col I, Col IV, and KLK7 degrades FN [15]. Our KLK4–7 data indicate 384 
that, as with MMPs [38], a more complex regulatory event that influences integrin levels and 385 
binding capacity to specific ECM proteins (VN/FN), both key elements in cancer metastasis. 386 
KLK4–7–expression in EOC cells did not alter attachment to Col I and Col IV, but attachment 387 
decreased to FN and VN. 388 
Integrins are strongly implicated in EOC dissemination, adhesion onto the mesothelial lining of 389 
the peritoneal cavity and subsequent invasion of the organs of the small pelvis [16, 17, 39]. The 390 
observed reduced cell adhesion of KLK4–7–transfected cells to FN and VN, which was further 391 
decreased by functional blocking αv/β1 integrin antibodies, indicates an interaction between the 392 
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KLK and integrin pathways. These data are also consistent with our previous report that KLK7–393 
SKOV–3 EOC cells form multicellular aggregates in 3–dimensional suspension via an α5/β1 394 
integrin–mediated process [13]. Reduced E–cadherin levels also stimulate α5/β1 integrin 395 
expression, cell adhesion, invasion and MAPK signalling, in particular via ERK1 in ovarian 396 
cancer cells [40]. Reduced E–cadherin expression has also been linked to the action of other 397 
proteases, such as MMP–9, that are enzymatic contributors to EOC disease progression [3, 39, 398 
41]. KLK4 (unpublished data), KLK6 [42] and KLK7 [43] can cleave the ectodomain of E–399 
cadherin, thus suggesting a role in maintenance of this phenotype and EOC cell shedding from 400 
the primary tumour into the peritoneal cavity [15, 40]. However, the EOC cell line used to 401 
overexpress KLK4–7 in our study, OV–MZ–6, does not express E–cadherin [28], thus this 402 
pathway may be constitutively active to maintain cell responses [35]. In this regard, we detected 403 
basal phosphorylated MAPK levels in these cells. These data further demonstrate that the 404 
KLK4–7 peptidases, both individually and as a group, have specific regulatory roles in the 405 
complex EOC microenvironment. 406 
 407 
Differential expression of paclitaxel–resistance associated factors 408 
The OV–MZ–6 cell line was established from a patient with an advanced cystadeno ovarian 409 
carcinoma after surgery without having received any chemotherapy [23] and was used to 410 
overexpress KLK4–7. The observed paclitaxel–resistance, indicative of a decreased cell survival, 411 
was detectable at a dose close to peak plasma concentration, approximately 5 nmol/L paclitaxel, 412 
with significant differences for the control and transfected OV–MZ–6 cell line seen at 10 to 100 413 
nmol/L paclitaxel. 414 
We reported earlier elevated α5β1 integrin levels upon KLK7 expression in SKOV–3 EOC cells, 415 
in EOC cells derived from ascites and in tumour tissues, as well as an KLK7 association with 416 
poor response of patients to chemotherapy [13]. Although combined KLK4–7 overexpression in 417 
untreated OV–MZ–6 EOC cells displayed reduced α5/β1 integrin levels compared to vector 418 
controls, paclitaxel treatment caused an increase in β1 integrin levels in the paclitaxel–insensitive 419 
cells. These results in a different EOC cell line expand on our previous data [13] and elaborate a 420 
KLK4–7 functional role partially in conjunction with selected members of the integrin axis in 421 
chemoresponsiveness of EOC cells. Although resistance to paclitaxel is not elucidated by a 422 
single genetic event or mechanism but rather due to alignment of multiple factors mediating cell 423 
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growth and survival [44]. The crosstalk of integrins with growth factor and/or cytokine receptors 424 
has cancer–promoting effects contributing to tumour metastasis and drug–resistance [16]. The β1 425 
integrin–dependent pathway associated with chemokine (C–X–C–motif) receptor 4 (CXCR4) 426 
was identified to be elevated in advanced ovarian cancer [45]. Cell survival signalling via 427 
integrin–CXCR4 is as part of the tumour–associated microenvironment which in turn conferred 428 
drug–resistance and tumour cell growth [46]. We detected decreased CXCR4 levels in 429 
paclitaxel–resistant KLK4–7–expressing cells and increased levels in paclitaxel–sensitive vector 430 
controls upon paclitaxel treatment; its ligand, stromal–derived factor–1 (SDF–1/CXCL12) did 431 
not change (data not shown). 432 
Adhesion to ECM components is another chemoresistance–promoting event. KLK4–7–433 
expressing cells capable of attachment to FN did not protect them from apoptosis induced by 434 
paclitaxel nor did the blocking β1 integrin antibody reduce apoptosis (data not shown). ERK–435 
induced apoptosis can occur due to cell detachment caused by decreased integrin levels [35]. The 436 
composition of cell–ECM interactions is far more complex, and protective tumour 437 
microenvironmental effects from paclitaxel–induced apoptosis are dependent on specific ECM 438 
proteins, integrin heterodimers and cell type [18, 47]. In fact, levels of integrin subunits vary 439 
between drug–resistant subpopulations [48]. Expression of αvβ3 integrin made cells partially 440 
resistant to paclitaxel [49]. However, αvβ3 integrin was downregulated upon KLK4–7 441 
expression and did not alter upon paclitaxel treatment and β1 integrin increased marginally upon 442 
treatment. As shown by others, no association between β1/β3 integrin subunits and survival rate 443 
was found in patients treated with platinum–based chemotherapy [50]. Overall, the direct 444 
relationship between the KLK4–7 peptidases, integrins and chemoresistance still needs to be 445 
further elucidated. 446 
 447 
It was shown that nanomolar concentrations of paclitaxel can affect the shape of the nucleus, 448 
whereas micromolar doses promote stress–induced pro–apoptotic pathways, associated with 449 
drug–resistance in ovarian cancer [32, 33]. Regulation of cytokeratins also plays a role in drug–450 
resistance [51]. Paclitaxel–treated KLK4–7–expressing cells showed a downregulation of 451 
cytokeratin8 and a minor increase in vector controls, while cytokeratin18 was upregulated 452 
independent of KLK4–7 expression. In line with other data, paclitaxel–resistant cancer cells 453 
revealed higher cytokeratin18 expression than paclitaxel–sensitive controls [52]. The 454 
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intermediate filaments cytokeratin8/18 and vimentin are co–expressed [23], and increased 455 
vimentin levels are associated with chemoresistance [51], but the molecular mechanism between 456 
drug–resistance and intermediate filaments still requires further clarification. It was postulated 457 
that increased invasive behaviour of epithelial cancer cells expressing both cytokeratins and 458 
vimentin may have a selective survival advantage [51]. Collectively, our data reported here and 459 
earlier [13, 22], underpin this hypothesis linking enhanced invasion and chemoresistance upon 460 
KLK expression in EOC cells with the simultaneous presence of intermediate filaments and 461 
vimentin. 462 
 463 
KLKs promote MAPK and other signalling cascades in paclitaxel–treated EOC cells 464 
We demonstrated that paclitaxel treatment of KLK4–7–expressing cells was associated with 465 
increased phosphorylation of ERK1 which occurs via a β1 integrin independent pathway as we 466 
only detected a slight increase in β1 integrin expression. Moreover, paclitaxel treatment of 467 
paclitaxel–insensitive vector controls decreased the activation of ERK1. Activation of ERK1/2, 468 
in particular ERK1, is linked to chemoresistance [18]. Another study showed that ERK1 was also 469 
activated upon paclitaxel treatment of EOC cells, but at much higher concentrations [53]. Since, 470 
however, the β1 integrin blocking antibody had no effect on ERK1/2 signalling upon paclitaxel 471 
treatment, ERK1 activation in our study is unlikely mediated to any large extent by integrin 472 
signalling. 473 
KLKs may be involved in activation of the ERK1/2 pathway via either direct activation of 474 
protease–activated receptors (PARs) or indirectly via epidermal growth factor receptor (EGFR) 475 
transactivation of PARs [37, 54-57]. Consequently, PAR–stimulated ERK1/2 activation 476 
influences cell proliferation and survival [54]. It was shown that EGFR expression and activity is 477 
upregulated upon integrin engagement with FAK and MAPK exhibiting a synergistic response in 478 
the crosstalk between integrins and EGFR in EOC cells [17]. The involvement of EGFR in 479 
paclitaxel–resistance in EOC cells was reported previously by others [58]. 480 
ERK activity has also been involved in apoptosis, for example due to transiently enhanced 481 
apoptotic activities induced by various anti–cancer compounds, including paclitaxel [35]. 482 
ERK1/2 inhibition of paclitaxel–treated cancer cells prevented cell death [35], an effect also 483 
observed in our study showing that the KLK4–7–induced paclitaxel resistance was not blocked 484 
by the MEK1/2 (U0126) inhibitor. This is in line with other reports showing that ERK1/2 485 
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inhibition reduced the ability of paclitaxel to mediate cell death in cancer cells, thus providing 486 
protection from paclitaxel–induced apoptosis [59]. The MAPK pathway is known for its 487 
oncogenic potential to increase cell survival by mediating anti–apoptotic stimuli, but recent data 488 
also suggest that aberrant ERK activation can induce apoptosis [35]. 489 
Recent data have demonstrated that a phase II trial using the MEK inhibitor selumentinib 490 
(AZD6244), reducing the activity of the MAPK pathway by blocking both MEK1 and MEK2 491 
enzymes, given to patients who had failed multiple rounds of cytotoxic chemotherapy, showed 492 
81% disease control (Cancer Discovery, 2012). Therefore, a combination therapy using MEK 493 
and kallikrein inhibitors, depending on the kallikrein expression of the tumour tissue, would be a 494 
novel approach to treat patients who become chemoresistant to the current therapy regime for 495 
advanced ovarian cancer potentially slowing down disease progression. 496 
 497 
In conclusion, we demonstrated that KLK4, KLK5, KLK6, and KLK7, when co–expressed in an 498 
EOC cell line representative of late stage disease, functionally contribute to a ECM–integrin 499 
crosstalk and activation of MAPK signalling implicated in chemoresistance to the clinically–500 
administered drug, paclitaxel, but not to carboplatin. The complex interplay with factors 501 
independent of integrin and MAPK cascades supports a role for these KLKs as partners in 502 
proteolytically critical cascades promoting ovarian cancer progression. Our study further 503 
underscores their potential as bioindicators for advanced disease, characterised by peritoneal 504 
dissemination and invasion, and their value as key therapeutic targets. 505 
 506 
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Figure legends 690 
 691 
Figure 1: Levels of KLK expression quantified by RT–qPCR and CLSM. A. KLK4, KLK5, 692 
KLK6 and KLK7 mRNA expression in combined OV–KLK4–7–transfected cells was confirmed 693 
by RT–qPCR, with OVCAR–3 cells showing endogenous levels (n=3; SEM). Parental OV–MZ–694 
6 and OV–Vector cells were negative for KLK expression (n.d., not detected). B. On 695 
immunofluorescent staining, KLK4, KLK6 and KLK7 expression was shown in OV–KLK4–7 696 
cells with low levels of KLK5 and negative staining in vector controls. Cytokeratin8 was stained 697 
with its respective primary and Alexa568–conjugated antibody, nuclei with DAPI, and KLKs 698 
with respective primary and Alexa488–conjugated antibodies. Scale bars, 20 µm. 699 
 700 
Figure 2: Altered cell adhesion and integrin expression of OV–KLK4–7 cells. A. Cell 701 
adhesion of OV–KLK4–7 cells to FN and VN was decreased compared to vector controls. No 702 
difference in the adhesive behaviour between OV–KLK4–7 and OV–Vector to Col I and Col IV 703 
was observed. B. Using a blocking β1 integrin antibody, cell attachment of both OV–KLK4–704 
7/OV–Vector cells to FN was reduced compared to the IgG control. Additionally, a statistically 705 
significant reduction of cell adhesion for OV–Vector cells to VN was observed. Blocking of αv 706 
integrin did not inhibit cell adhesion to FN, but reduced cell adhesion of both OV–KLK4–7/OV–707 
Vector cells to VN compared to the IgG control, with OV–KLK4–7 cells being less adhesive 708 
than vector controls. OV–KLK4–7 cells were more adhesive to FN after αv integrin inhibition 709 
(n=3; SEM; * – P<0.05; ** – P<0.01; *** – P<0.001). C. RT–qPCR showed decreased mRNA 710 
levels of αv/α5/β1 integrins in OV–KLK4–7 cells compared to vector controls; β3 integrin did 711 
not change (n=3; SEM; ** – P<0.01; *** – P<0.001). D. Flow cytometrical analyses showed 712 
that OV–KLK4–7 and OV–Vector cells expressed high α5/β1 and very low αvβ3 integrin levels. 713 
Normalisation of flow cytometry data to OV–Vector cells revealed that OV–KLK4–7 cells have 714 
significantly decreased αvβ3/β1 integrin levels (n=3; SEM; * – P<0.05; ** – P<0.01). E. 715 
Presence of α5/β1/α5β1 integrins in both OV–KLK4–7/OV–Vector cells was further confirmed 716 
by immunofluorescent staining visualised by CLSM using the respective primary and Alexa488–717 
conjugated secondary antibodies. Cell actin filaments were stained with rhodamine415–718 
conjugated phalloidin, nuclei with DAPI. Scale bars, 10 µm. 719 
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Figure 3: Paclitaxel–induced chemoresistance of OV–KLK4–7 cells. A. Administration of 721 
paclitaxel enhanced OV–KLK4–7 cell survival (10/50/100 nmol/L) compared to vector controls. 722 
For a dose of 10/50/100 nmol/L, the OV–Vector cell survival was 24/14/13% and for OV–723 
KLK4–7 cells 33/21/20%; setting 24/14/13% to 100%, an OV–KLK4–7 cell survival difference 724 
of 38/49/54% compared to OV–Vector was reached (n=3; SEM; * – P<0.05; ** – P<0.01). B. 725 
Both OV–KLK4–7/OV–Vector cells responded equally to carboplatin treatment (n=3; SEM). C. 726 
Exposure of paclitaxel (100 nmol/L) on day 1 followed by media/carboplatin (50 µmol/L) on day 727 
3 (P–M–M/P–M–C) caused less OV–KLK4–7 cell death compared to vector controls. Presence 728 
of carboplatin/media on day 1 followed by media/paclitaxel/carboplatin on day 3 (C–M–M/C–729 
M–P/M–M–P/M–M–C) increased cell survival, with OV–KLK4–7 cells being less responsive to 730 
paclitaxel compared to vector controls (n=3; SEM; * – P<0.05; ** – P<0.01; *** – P<0.001). 731 
 732 
Figure 4: Paclitaxel–induced chemoresistance of OV–KLK4–7 cells due to decreased 733 
apoptotic expression. A. Stable microtubules (indicated by white arrows) formed by tubulin 734 
dimers upon paclitaxel treatment of both OV–KLK4–7/OV–Vector cells over 48 h were 735 
immunofluorescently visualized by CLSM using anti–α–tubulin and Alexa488–conjugated 736 
secondary antibody. Both, typical oval–shaped nuclei (indicated by yellow arrows) as well as 737 
lobulated and multiple micronuclei were detected (indicated by green arrows). Cell actin 738 
filaments were stained with rhodamine415–conjugated phalloidin, nuclei with DAPI. Scale bars, 739 
25 µm. B. Expression of caspase8 and cytokeratin8 was decreased on 48 h paclitaxel treatment 740 
in chemoresistant OV–KLK4–7 cells, while expression of cytokeratin18 was enhanced in both 741 
OV–KLK4–7/OV–Vector cells (n=3/4; SEM; * – P<0.05; ** – P<0.01). C. Stable microtubules 742 
(indicated by white arrows) formed by tubulin dimers upon paclitaxel treatment over 48 h of 743 
both OV–KLK4–7/OV–Vector cells were immunofluorescently visualized by CLSM using anti–744 
α–tubulin and Alexa488–conjugated secondary antibody. Propidium iodide was used to stain 745 
double–stranded nucleic acids as it penetrates cell membranes of dead cells. Nuclei were 746 
counterstained with DAPI. Additionally, annexin V was used to stain apoptotic cells due to loss 747 
of cell membrane integrity with anti–annexin V and Alexa488–conjugated secondary antibody. 748 
Scale bars, 25 µm. 749 
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Figure 5: Paclitaxel–induced chemoresistance of OV–KLK4–7 cells due to phosphorylation 751 
of ERK. A. Western blot analyses revealed enhanced ERK1/2 phosphorylation and increased β1 752 
integrin expression in OV–KLK4–7 cells due to paclitaxel treatment compared to vector 753 
controls. Src activation was minimal and did not change upon chemotreatment. B. Paclitaxel 754 
treatment caused significant activation of ERK1 and enhanced β1 integrin expression in OV–755 
KLK4–7 cells compared to OV–Vector cells as indicated by densitometry of Western blots 756 
represented in panel A; no altered expression and phosphorylation of Src was detected after 757 
treatment (n=3; SEM; * – P<0.05; ** – P<0.01). C. Inhibition experiments using β1 integrin 758 
blocking antibody, Src (SU6656) and MEK1/2 (U0126) inhibitors pre–exposed to cells before 759 
chemotreatment showed that the MEK1/2 pathway was involved in the response of both OV–760 
KLK4–7/OV–Vector cells to paclitaxel. D. Chemosensitivity assays demonstrated enhanced 761 
OV–KLK4–7 cell survival upon MEK1/2 inhibition and paclitaxel treatment (10/100 nmol/L) 762 
compared to vector controls (n=3; SEM; * – P<0.05; ** – P<0.01; ***/ P###P – P<0.001). 763 
 764 
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Table 1. Gene expression performed by RT–qPCR upon paclitaxel treatment. Relative 766 
mRNA expression of integrins and the integrin–related factor CXCR4 (n=3; SEM; * – P<0.05). 767 
 768 
Gene Cell type No treatment (± SEM) Paxlitaxel treatment (± SEM) 
α5 integrin OV–Vector 5.02x10P-3 P ± 9.62x10P-4 5.16x10P-3 P ± 9.14x10P-4 
 OV–KLK4–7 3.76x10P-3 P ± 4.59x10P-4 3.55x10P-3 P ± 3.56x10P-4 
αv integrin OV–Vector 1.49x10P-4 P ± 9.98x10P-5 9.80x10P-5 P ± 3.37x10P-5 
 OV–KLK4–7 5.68x10P-5 P ± 2.97x10P-5 4.64x10P-5 P ± 7.95x10P-6 
β1 integrin OV–Vector 1.14x10P-4 P ± 8.56x10P-6 1.50x10P-4 P ± 2.04x10P-5 
 OV–KLK4–7 5.86x10P-5 P ± 6.79 x10P-6 5.01x10P-5 P ± 3.01x10P-6 
β3 integrin OV–Vector 4.06x10P-5 P ± 1.81x10P-5 3.66x10P-5 P ± 1.50x10P-5 
 OV–KLK4–7 3.84x10P-5 P ± 1.69x10P-5 2.95x10P-5 P ± 6.81x10P-6 
CXCR4 OV–Vector 1.04x10P-3 P ± 3.57x10P-4 1.09x10P-3 P ± 9.75x10P-5 
 OV–KLK4–7 1.21x10P-3 P ± 4.68x10P-4 6.35x10P-4 P ± 1.87x10P-4 
 769 
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